Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAN J DICKSTEIN

Allopathic & Osteopathic Physicians Urology

NPI
1407026487
CMS profile
630760
Location
HANOVER, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$22,454.60

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $15,065.00 7
Consulting Fee $4,055.56 2
Food and Beverage $2,274.04 66
Travel and Lodging $1,060.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAN J DICKSTEIN

NPI 1407026487 · CMS profile ID 630760

Allopathic & Osteopathic Physicians / Urology

HANOVER, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407026487?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAN J DICKSTEIN, NPI 1407026487, CMS profile ID 630760. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407026487?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RIAN J DICKSTEIN, NPI 1407026487, CMS profile ID 630760. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407026487?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RIAN J DICKSTEIN, NPI 1407026487, CMS profile ID 630760, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1407026487?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $22,454.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–76 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $20.7406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996691977 CMS
Sumitomo Pharma America, Inc. $21.5906/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030959989 CMS
Seagen Inc. $15.5406/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995662313 CMS
Olympus America Inc. $19.4205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035406065 CMS
Astellas Pharma US Inc $25.7005/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034090839 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.6405/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000869119 CMS
Antares Pharma, Inc. $18.9204/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054579381 CMS
Tolmar, Inc. $29.6804/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056966149 CMS
Astellas Pharma US Inc $21.7603/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034019306 CMS
Coloplast Corp $23.2703/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993580847 CMS
Sumitomo Pharma America, Inc. $22.4403/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030959969 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.1503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000843371 CMS
Boston Scientific Corporation $10.0802/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021949429 CMS
Dendreon Pharmaceuticals LLC $26.6802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060282975 CMS
E.R. Squibb & Sons, L.L.C. $300.0002/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015561887 CMS
Astellas Pharma US Inc $17.4902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033894123 CMS
Medtronic, Inc. $95.0002/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019656497 CMS
Boston Scientific Corporation $6.5701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021949425 CMS
Janssen Biotech, Inc. $19.0401/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988277455 CMS
Alnylam Pharmaceuticals Inc. $27.8201/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006126821 CMS
UroGen Pharma, Inc. $1,600.0001/18/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061153019 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.7501/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000887529 CMS
Astellas Pharma US Inc $4.8301/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033857136 CMS
AVEO Pharmaceuticals, Inc. $16.4801/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049064733 CMS
Boston Scientific Corporation $108.0301/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021949435 CMS
Endo Pharmaceuticals Inc. $16.5401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033319179 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,414.54 64
PY2020 $2,000.39 20
PY2021 $29,300.41 90
PY2022 $24,767.28 99
PY2023 $22,454.60 76
PY2024 $24,507.42 106
PY2025 $35,327.77 126

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $132,190.89 10
PY2024 Principal investigator $87,890.94 15
PY2023 Principal investigator $70,471.83 18
PY2022 Principal investigator $132,156.75 23
PY2021 Principal investigator $130,574.19 40
PY2020 Principal investigator $27,414.12 7
PY2019 Principal investigator $25,794.04 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,140.00 11/03/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175382939
Principal investigator 1 PFIZER INC. $574.60 10/08/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228741768
Principal investigator 1 Janssen Research & Development, LLC $3,209.00 09/08/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175382768
Principal investigator 1 Janssen Research & Development, LLC $3,209.00 04/28/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175382908
Principal investigator 1 PFIZER INC. $2,451.80 03/28/2025 Non-covered Recipient Entity
Chesapeake Urology Research Associates
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228782142
Principal investigator 1 Janssen Research & Development, LLC $2,920.00 03/21/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175382760
Principal investigator 1 Janssen Research & Development, LLC $3,038.00 03/10/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175383021
Principal investigator 1 Janssen Research & Development, LLC $38,000.00 02/10/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175382723
Principal investigator 1 AstraZeneca Pharmaceuticals LP $73,439.49 01/29/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES, PA
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185550851
Principal investigator 1 Janssen Research & Development, LLC $3,209.00 01/02/2025 Non-covered Recipient Entity
CHESAPEAKE UROLOGY ASSOCIATES LLC D BA CHESAPEAKE UROLOGY RESEARCH ASSO
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175382923

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $80,182.17 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $78,612.01 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $37,950.63 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $35,239.87 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $90,358.69 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $39,494.35 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $204.38 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771375
PY2024 SN Holdings, LLC $0.00 $79,977.79 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773123
PY2023 SN Holdings, LLC $0.00 $78,612.01 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887101
PY2022 SN Holdings, LLC $0.00 $37,950.63 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609109
PY2021 SN Holdings, LLC $0.00 $35,239.87 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820124729
PY2020 UroGPO LLC $0.00 $90,358.69 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139249
PY2019 UroGPO LLC $0.00 $39,494.35 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690774825